Comprehensive Monograph: Roflumilast (DB01656)

Section 1: Molecular Profile and Physicochemical Characteristics

Roflumilast is a small molecule drug that represents a significant therapeutic advancement in the management of specific inflammatory diseases. Its development and application are rooted in its precise chemical structure and distinct physicochemical properties, which dictate its interaction with its biological target and its behavior within the human body. This section provides a foundational overview of the molecule's chemical identity, nomenclature, and key physical characteristics.

1.1 Chemical Identity and Nomenclature

Roflumilast is chemically classified as a benzamide derivative. Its structure is the result of the formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine.[1] This specific arrangement of functional groups, including an aromatic ether, a chloropyridine, an organofluorine compound, and a cyclopropane member, is critical to its pharmacological activity.[1]

The molecule is identified across scientific and regulatory domains by a set of standardized names and codes:

• Systematic (IUPAC) Name: 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide.[1]
• Generic Name: Roflumilast.
• CAS Number: 162401-32-3, its unique registry number assigned by the Chemical Abstracts Service.[1]
• DrugBank ID: DB01656, its accession number in the comprehensive DrugBank database.[1]

The chemical formula for Roflumilast is C17​H14​Cl2​F2​N2​O3​, corresponding to a molar mass of 403.21 g·mol⁻¹.[2] The intricate combination of the benzamide core, the dichloropyridine ring, and the distinct cyclopropylmethoxy and difluoromethoxy side chains is not arbitrary. This architecture has been deliberately engineered for high-affinity and selective binding to the active site of its enzymatic target, phosphodiesterase-4 (PDE4). The inclusion of the organofluorine difluoromethoxy group, a common motif in modern medicinal chemistry, serves to enhance metabolic stability and binding affinity. This structural feature is a direct contributor to the drug's high potency and its favorable pharmacokinetic profile, including a long elimination half-life, which underpins its clinical utility.

1.2 Physicochemical Properties

The physical and chemical properties of Roflumilast influence its formulation, stability, and biological disposition.

• Physical Appearance: The compound is a white or off-white powder or may present in a crystalline form.[3]
• Melting Point: Roflumilast has a distinct melting point of 158°C, a key physical constant that indicates its purity and thermal stability in the solid state.[1]
• Solubility: It is described as sparingly soluble in aqueous solutions.[1] This property is a critical consideration for its oral absorption characteristics. For laboratory and research purposes, it demonstrates high solubility in organic solvents such as dimethyl sulfoxide (DMSO), where it can be dissolved at concentrations up to 81 mg/mL (200 mM) at 25°C.[3] This solubility profile is essential for conducting in vitro experiments and high-throughput screening assays.
• Dissociation Constant (pKa​): The molecule has a pKa​ of 8.74.[1] This value is important as it determines the degree of ionization of the molecule at physiological pH, which in turn affects its membrane permeability, absorption, distribution, and binding to its target.

Identifier	Value
Systematic (IUPAC) Name	3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
Generic Name	Roflumilast
DrugBank ID	DB01656
CAS Number	162401-32-3
PubChem CID	449193
UNII	0P6C6ZOP5U
ChEMBL ID	CHEMBL193240
KEGG ID	D05744
ATC Code	R03DX07 (Systemic), D05AX06 (Topical)
Molecular Formula	C17​H14​Cl2​F2​N2​O3​
Molar Mass	403.21 g·mol⁻¹
InChI	InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
InChIKey	MNDBXUUTURYVHR-UHFFFAOYSA-N
SMILES	C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F

Section 2: Pharmacological Profile: Mechanism of Action as a Selective PDE4 Inhibitor

The therapeutic efficacy of Roflumilast is derived from its highly specific interaction with the phosphodiesterase-4 (PDE4) enzyme. By modulating a fundamental intracellular signaling pathway, Roflumilast exerts potent anti-inflammatory and immunomodulatory effects that are central to its clinical utility in both respiratory and dermatological diseases.

2.1 The Phosphodiesterase-4 (PDE4) Enzyme Family

Phosphodiesterases (PDEs) constitute a large superfamily of enzymes that serve as critical regulators of intracellular signaling by catalyzing the hydrolysis of the cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP) and cyclic-3',5'-guanosine monophosphate (cGMP).[5] The PDE4 family, which comprises four gene-encoded isoforms (PDE4A, PDE4B, PDE4C, and PDE4D), is distinguished by its absolute specificity for cAMP.[5]

The strategic importance of PDE4 as a therapeutic target stems from its predominant expression in nearly all cells involved in inflammatory and immune responses. These include key effector cells such as neutrophils, eosinophils, macrophages, T-lymphocytes, and dendritic cells, as well as structural cells like airway smooth muscle cells and epithelial cells.[1] The widespread distribution of PDE4 isoforms throughout the body, including in the lungs, skin, and central nervous system, implicates them in the regulation of essential physiological processes. Consequently, dysregulation of PDE4 activity is a key pathogenic feature in chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and various inflammatory dermatoses, including psoriasis and atopic dermatitis.[5]

2.2 Selective Inhibition of PDE4 and Accumulation of cAMP

Roflumilast and its principal active metabolite, roflumilast N-oxide, function as highly potent and selective inhibitors of the PDE4 enzyme.[1] This high degree of potency is demonstrated by their low half-maximal inhibitory concentration (

IC50​) values, which are in the nanomolar range (0.2–0.9 nM) for various PDE4 subtypes.[7]

A defining characteristic of Roflumilast's pharmacological profile is its exceptional selectivity. It is effectively inactive against other PDE isoenzymes, such as PDE1, PDE2, PDE3, PDE5, and PDE7.[4] This specificity is crucial for its therapeutic window. Inhibition of other PDE families would lead to significant off-target effects; for example, PDE3 inhibition is associated with cardiovascular effects, while PDE5 inhibition is the mechanism of action for drugs used to treat erectile dysfunction. Roflumilast's targeted action on PDE4 localizes its primary effects to the inflammatory cascade, explaining its utility in diseases like COPD and psoriasis without inducing widespread, unrelated physiological changes. This also explains why Roflumilast is not a direct bronchodilator, a property that would be expected from a non-selective PDE inhibitor like theophylline or a PDE3 inhibitor.[8]

The fundamental molecular consequence of PDE4 inhibition by Roflumilast is the prevention of intracellular cAMP degradation. This leads to the accumulation of cAMP within target cells.[4] The resulting elevation in intracellular cAMP concentration is the pivotal event that initiates the downstream signaling cascades responsible for the drug's therapeutic effects.[1]

2.3 Downstream Anti-Inflammatory and Immunomodulatory Effects

The accumulation of intracellular cAMP triggers a broad spectrum of anti-inflammatory and immunomodulatory responses.[5] This single molecular event translates into widespread suppression of the inflammatory processes that drive diseases like COPD and psoriasis.

In the context of respiratory disease, the elevated cAMP levels in immune cells lead to the downregulation of a host of pro-inflammatory cytokines and mediators. This includes the suppression of key molecules such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), IL-1β, and leukotrienes.[5] Direct evidence of this anti-inflammatory action in the lungs comes from pharmacodynamic studies in COPD patients, which have shown that Roflumilast treatment significantly reduces the number of sputum neutrophils by 31% and eosinophils by 42%.[15]

A similar mechanism is operative in dermatological diseases. In the skin, PDE4 inhibition modulates the local immune response by decreasing the production of key inflammatory cytokines implicated in the pathogenesis of psoriasis and atopic dermatitis, such as interferon-gamma (IFN-γ), TNF-α, IL-4, IL-17, and IL-23.[17] This targeted suppression of cutaneous inflammation helps to restore the balance of the skin barrier and alleviate the clinical signs and symptoms of these conditions.

2.4 A Novel Mechanism: Interruption of the AcPGP Pro-Neutrophilic Pathway

Recent research has uncovered a more nuanced and potentially disease-modifying mechanism of Roflumilast in COPD, involving its interaction with the acetyl-proline-glycine-proline (AcPGP) pathway.[13] AcPGP is a collagen-derived peptide that acts as a potent neutrophil chemoattractant, and its pathway is described as a "self-propagating" cycle that perpetuates chronic neutrophilic inflammation, a hallmark of severe COPD.

A pivotal randomized controlled trial provided direct evidence of Roflumilast's impact on this pathway. The study found that 12 weeks of Roflumilast treatment resulted in a greater than 50% decrease in sputum AcPGP levels and a 46% reduction in the activity of prolyl endopeptidase, the enzyme responsible for AcPGP production.[13]

This finding represents a significant advancement in understanding the drug's efficacy. It suggests that Roflumilast does more than simply suppress ongoing inflammation; it actively interrupts a key feed-forward loop that drives the recurrence of inflammatory episodes. By halting this self-perpetuating cycle, Roflumilast lessens the overall inflammatory burden in the airways. This provides a powerful mechanistic rationale for its specific clinical indication—reducing the risk of exacerbations in the "frequent exacerbator" phenotype—and suggests that its long-term benefit may extend to altering the natural history of the disease in susceptible patients. This potential disease-modifying role distinguishes it from therapies that offer purely symptomatic relief.

Section 3: Pharmacokinetics and Metabolism: Oral and Topical Formulations

The clinical application and safety profile of Roflumilast are directly governed by its pharmacokinetic properties, which differ substantially between its oral and topical formulations. A comprehensive understanding of its absorption, distribution, metabolism, and excretion (ADME) is essential for optimizing therapy, managing drug interactions, and appreciating the rationale behind its dual utility in systemic and localized diseases.

3.1 Oral Formulation Pharmacokinetics (ADME)

The oral formulation of Roflumilast is designed for systemic delivery to target inflammation in the lungs. Its pharmacokinetic profile is characterized by high bioavailability and the formation of a key active metabolite that sustains its therapeutic effect.

Absorption: Following oral administration, Roflumilast is rapidly and almost completely absorbed from the gastrointestinal tract. It exhibits a high absolute bioavailability of approximately 79-80%.[2] In a fasted state, the parent drug reaches its maximum plasma concentration (

Cmax​) quickly, with a time to maximum concentration (Tmax​) of 0.5 to 2 hours.[4] The presence of food alters the absorption rate but not the extent; a meal reduces the

Cmax​ by about 40% and delays the Tmax​ by one hour, but the total drug exposure, as measured by the area under the concentration-time curve (AUC), remains unchanged.[4]

Distribution: Roflumilast and its active metabolite, roflumilast N-oxide, are both extensively bound to plasma proteins, at approximately 99% and 97-99%, respectively.[2] This high degree of protein binding limits the concentration of free, pharmacologically active drug in the circulation and suggests a large volume of distribution throughout the body.

Metabolism: Roflumilast undergoes extensive hepatic metabolism through both Phase I (cytochrome P450-mediated) and Phase II (conjugation) reactions.[2] The most critical metabolic pathway is the N-oxidation of Roflumilast, a process mediated primarily by the

CYP1A2 and CYP3A4 isoenzymes, to form its major active metabolite, roflumilast N-oxide.[2]

Role of Roflumilast N-oxide: The N-oxide metabolite is a potent and selective PDE4 inhibitor with an efficacy comparable to the parent compound.[6] Its clinical significance, however, lies in its pharmacokinetic profile. The systemic exposure (AUC) of roflumilast N-oxide is approximately

10 times greater than that of Roflumilast itself.[6] This, combined with its longer half-life, makes roflumilast N-oxide the primary driver of the total PDE4 inhibitory activity in vivo, accounting for an estimated 90% or more of the overall pharmacologic effect.[6] This "prodrug-like" characteristic, where the metabolite is responsible for the majority of the sustained therapeutic action, is a cornerstone of the drug's once-daily dosing regimen and a key factor in its susceptibility to drug-drug interactions involving CYP enzymes.

Excretion: The body eliminates Roflumilast predominantly through metabolism into inactive compounds, which are then excreted mainly in the urine (approximately 70%).[2] The elimination half-life is notably long, averaging around

17 hours for Roflumilast and 30 hours for roflumilast N-oxide.[2] This prolonged half-life of the active metabolite ensures sustained PDE4 inhibition over a 24-hour period, providing the rationale for once-daily administration.

3.2 Topical Formulation Pharmacokinetics

The topical formulations of Roflumilast were developed to deliver the drug directly to the skin, maximizing local efficacy while minimizing systemic exposure and its associated adverse effects.

Absorption and Bioavailability: In stark contrast to the oral route, topical administration of Roflumilast cream results in very low systemic absorption. A pharmacokinetic study of the 0.3% cream formulation determined the systemic bioavailability to be only 1.5%.[26] This minimal systemic uptake is the key feature that separates the safety profiles of the oral and topical products.

Plasma Concentrations: The absorption kinetics from the skin are slow and sustained. This results in a flat plasma concentration-time profile, with a peak-to-trough ratio of only 1.2, which is indicative of continuous, low-level release from the skin into the systemic circulation rather than the distinct peak seen after oral dosing.[26]

Skin Concentration and Reservoir Effect: The primary goal of topical delivery is achieved, as Roflumilast concentrations in the skin are dramatically higher—on average, 61.8- to 126-fold higher—than the corresponding plasma concentrations.[26] This demonstrates that the drug effectively penetrates the stratum corneum to form a local reservoir, delivering high concentrations of the active substance directly to the target tissue where the inflammation occurs.

Metabolism and Half-Life: Another crucial distinction is that there is no significant conversion of Roflumilast to its N-oxide metabolite within the skin.[26] This means that the parent drug, Roflumilast, is the primary pharmacologically active moiety at the site of dermatological action. The terminal half-life after the last topical dose is very long, approximately 4.0 days for Roflumilast and 4.6 days for the small amount of N-oxide that is formed systemically, consistent with the slow and prolonged release of the drug from its reservoir in the skin.[26] This pharmacokinetic separation—high local concentration, low systemic absorption, and local activity of the parent drug—is the foundation of Roflumilast's successful repurposing as a topical anti-inflammatory agent, effectively decoupling its dermatological efficacy from the systemic side effects of the oral formulation.

Parameter	Roflumilast (Oral)	Roflumilast N-oxide (from Oral)	Roflumilast (Topical)	Roflumilast N-oxide (from Topical)
Bioavailability	~80%	N/A (Metabolite)	~1.5%	N/A (Metabolite)
Tmax​ (Time to Peak)	0.5–2 hours	~8 hours	N/A (Flat Profile)	N/A (Flat Profile)
Protein Binding	~99%	~97-99%	N/A	N/A
Elimination Half-life	~17 hours	~30 hours	~4.0 days	~4.6 days
Relative Exposure (AUC)	1x	~10x (relative to parent)	Very low systemic exposure	~8x higher than parent (but both low)

Section 4: Clinical Efficacy in Approved Indications

The clinical development of Roflumilast has led to its approval for distinct indications in both respiratory and dermatological medicine. Its efficacy is most pronounced in specific patient populations, a finding that has underscored the importance of phenotype-driven therapy and the "treatable traits" model in managing chronic inflammatory diseases.

4.1 Management of Severe Chronic Obstructive Pulmonary Disease (COPD)

Oral Roflumilast is established as an add-on therapy for a well-defined subset of patients with COPD. It is not a bronchodilator and is not intended for the relief of acute symptoms; rather, its role is prophylactic, aimed at reducing the frequency of future inflammatory events.[8]

Approved Indication: Oral Roflumilast is indicated to reduce the risk of COPD exacerbations in patients with severe COPD, defined by a post-bronchodilator forced expiratory volume in 1 second (FEV1​) of less than 50% of the predicted value, who also have symptoms of chronic bronchitis (chronic cough and sputum) and a history of frequent exacerbations.[4]

Pivotal and Confirmatory Trial Evidence: The clinical development program for Roflumilast in COPD evolved from early trials that showed modest effects to large, pivotal trials that confirmed its efficacy in the target phenotype.

• Early Trials (RECORD, RATIO, EOS, HELIOS): Initial studies like the RECORD and RATIO trials provided the first signals of efficacy, demonstrating modest but statistically significant improvements in post-bronchodilator FEV1​.[27] While the effect on exacerbation rates was not consistently significant in the overall populations of these early trials, post-hoc analyses were instrumental. They suggested that the greatest benefit was concentrated in patients with more severe disease, chronic bronchitis, and a history of frequent exacerbations.[27] The EOS and HELIOS trials further supported its use as an add-on to long-acting bronchodilators, showing modest improvements in lung function.[27]
• Pivotal Trials (AURA & HERMES): Guided by the findings from earlier studies, the identical, year-long AURA and HERMES trials (n=3,091) specifically enrolled the target patient population. A pooled analysis of these studies demonstrated a clinically and statistically significant 17% reduction in the rate of moderate or severe exacerbations for patients treated with Roflumilast compared to placebo (p < 0.0003).[27] These trials also confirmed the modest but significant improvements in pre-bronchodilator FEV1​.[27]
• Add-on to Modern Therapy (REACT & RE2SPOND): To establish its role in the context of modern COPD management, the REACT and RE2SPOND trials evaluated Roflumilast as an add-on to intensive inhaled regimens.
• The REACT trial demonstrated that adding Roflumilast to a background of combination therapy (including inhaled corticosteroids/long-acting β2-agonists, and often a long-acting muscarinic antagonist [LAMA]) resulted in a significant reduction in the rate of exacerbations (Risk Ratio 0.858; p = 0.0424) and a reduction in hospital admissions compared to placebo.[27]
• The RE2SPOND trial did not meet its primary endpoint in the overall study population. However, a crucial post-hoc analysis revealed a significant reduction in exacerbations among the highest-risk patients—those with a history of more than three exacerbations or at least one hospitalization in the previous year.[39]

Trial Name(s)	ClinicalTrials.gov ID	Patient Population (N, FEV1%, Phenotype)	Duration	Concomitant Therapy Allowed	Primary Endpoint(s)	Key Efficacy Outcome
AURA & HERMES	NCT00297102, NCT00297115	N=3,091; Severe COPD (FEV1​ ≤50%); Chronic Bronchitis; History of exacerbations	52 weeks	LABA	Exacerbation Rate, Pre-bronchodilator FEV1​	17% reduction in moderate/severe exacerbations (p < 0.0003)
REACT	NCT01329029	N=1,935; Severe COPD (FEV1​ <50%); Chronic Bronchitis; ≥2 exacerbations in prior year	52 weeks	ICS/LABA ± LAMA	Exacerbation Rate	Significant reduction in exacerbations (RR 0.858, p=0.0424); Reduced hospital admissions
RE2SPOND	NCT01443845	N=2,354; Severe COPD (FEV1​ <50%); Chronic Bronchitis; ≥2 exacerbations in prior year	52 weeks	ICS/LABA FDC ± LAMA	Exacerbation Rate	Not met in overall population; Significant reduction in subgroup with >3 exacerbations or ≥1 hospitalization in prior year

4.2 The "Treatable Trait" Approach: Identifying Patient Subgroups for Optimal Response

The clinical journey of Roflumilast is a compelling illustration of the "treatable traits" model in respiratory medicine, where therapy is targeted not at a broad disease label but at specific, measurable patient characteristics.[27] The evidence strongly indicates that the benefit of Roflumilast is concentrated in a phenotype defined by several key traits:

1. Chronic Bronchitis: The presence of chronic cough and sputum production is a consistent predictor of response across multiple trials.[27]
2. History of Frequent or Severe Exacerbations: The greatest benefit is seen in patients with a high burden of past events, particularly those with two or more exacerbations or at least one hospitalization in the prior year. A pooled analysis of the REACT and RE2SPOND trials found that in patients with a prior hospitalization, Roflumilast reduced moderate or severe exacerbations by a substantial 25.6% (p=0.0005).[43]
3. Elevated Blood Eosinophils: This biomarker has emerged as another important predictive trait. The same pooled analysis showed a significantly greater treatment effect in patients with baseline blood eosinophil counts of 150 cells/µL or higher. In the high-risk subgroup of patients with both a prior hospitalization and elevated eosinophils (≥150 cells/µL), the reduction in exacerbations reached 34.5% (p=0.0003).[43] The identification of eosinophilia as a predictive marker challenges the traditional view of COPD as a purely neutrophilic disease and suggests that Roflumilast's broad anti-inflammatory action is effective at suppressing the underlying eosinophilic component present in this high-risk subgroup.

4.3 Topical Formulations in Inflammatory Dermatoses

Leveraging its potent anti-inflammatory mechanism while avoiding systemic side effects, topical Roflumilast (brand name Zoryve) has been successfully developed and approved for several common skin conditions.

Approved Indications:

• Plaque Psoriasis: The 0.3% cream is approved for patients aged 6 and older, and the 0.3% foam for patients aged 12 and older.[4]
• Atopic Dermatitis: The 0.15% cream is indicated for mild to moderate disease in patients aged 6 and older.[4]
• Seborrheic Dermatitis: The 0.3% foam is approved for patients aged 9 and older.[1]

Clinical Efficacy: Large-scale Phase III clinical trials, such as the DERMIS trials for psoriasis, have consistently demonstrated the superiority of roflumilast cream over its vehicle (placebo).[50] Key endpoints met in these trials include a significantly higher proportion of patients achieving Investigator Global Assessment (IGA) success, defined as a score of "clear" or "almost clear," and significant reductions in disease severity as measured by the Psoriasis Area and Severity Index (PASI). Furthermore, long-term open-label extension studies have confirmed that this efficacy is durable, with a favorable safety and tolerability profile maintained for up to 64 weeks of continuous use.[55]

4.4 Off-Label and Investigational Uses

The success of Roflumilast in its approved indications has spurred investigation into other inflammatory conditions.

• Oral Roflumilast in Dermatology: There is growing evidence from case reports, small series, and some randomized controlled trials for the off-label use of oral Roflumilast in various dermatological conditions. These include moderate-to-severe plaque psoriasis, hidradenitis suppurativa, recurrent oral aphthosis, and nummular eczema.[18] A real-world prospective cohort study involving 58 patients with moderate-to-severe psoriasis treated with oral Roflumilast found that 67.4% of patients achieved a 75% improvement in their PASI score (PASI75) by week 24.[58]
• Other Investigational Areas: The broad anti-inflammatory potential of PDE4 inhibition is being explored in diverse fields. Clinical trials are currently underway or have been completed to evaluate Roflumilast's potential in treating rosacea, chronic hand eczema, non-alcoholic steatohepatitis (NASH), and certain neurological disorders like Fragile X Syndrome.[18]

Section 5: Comprehensive Safety and Tolerability Profile

The clinical utility of Roflumilast is defined by a balance between its therapeutic benefits and its well-characterized safety and tolerability profile. While generally manageable, the adverse effects associated with the oral formulation necessitate careful patient selection, counseling, and monitoring. The adverse effect profile is a direct consequence of its systemic mechanism of action; PDE4 is widely expressed throughout the body, including in the gastrointestinal tract and the central nervous system. The increase in cAMP in these off-target tissues is the likely cause of the most common side effects, making them on-target but undesirable effects.

5.1 Common Adverse Events and Tolerability

The most frequently reported adverse reactions in controlled clinical trials of oral Roflumilast are predominantly gastrointestinal and neurological in nature.[2]

• Diarrhea: 9.5% of patients on Roflumilast vs. 2.7% on placebo.
• Weight Decrease: 7.5% vs. 2.1%.
• Nausea: 4.7% vs. 1.4%.
• Headache: 4.4% vs. 2.1%.
• Insomnia: 2.4% vs. 1.0%.

These events, particularly diarrhea and nausea, are the primary reasons for treatment discontinuation, accounting for 2.4% and 1.6% of discontinuations, respectively.[66] A key clinical observation is that these side effects typically manifest within the first few weeks of therapy and often resolve with continued treatment as the body acclimates.[67] To improve initial tolerability and reduce early discontinuation, a dose-escalation strategy is available. This involves starting treatment with a 250 mcg daily dose for the first four weeks before increasing to the full therapeutic dose of 500 mcg daily.[8]

5.2 Serious Adverse Events and Warnings

Beyond the common tolerability issues, oral Roflumilast carries warnings for more serious adverse events that require diligent monitoring.

Weight Loss: A decrease in body weight is a common and clinically significant adverse effect. In year-long clinical trials, 7% of patients treated with Roflumilast experienced severe weight loss (defined as >10% of body weight), compared to only 2% of patients on placebo.[66] The mechanism is thought to be related to the role of PDE4 in lipolysis. This effect necessitates regular weight monitoring for all patients on therapy. If a patient experiences unexplained or clinically significant weight loss, the treatment should be re-evaluated, and discontinuation should be considered.[24] Encouragingly, this weight loss has been shown to be largely reversible upon cessation of the drug.[27] While a clear adverse event, this effect may have different implications depending on the patient's baseline body mass index, presenting a greater risk for frail or underweight patients and a potentially neutral or even beneficial effect for overweight or obese patients, though monitoring remains essential for all.

Psychiatric Events: Treatment with Roflumilast is associated with an increased risk of psychiatric adverse reactions. In clinical trials, insomnia (2.4%), anxiety (1.4%), and depression (1.2%) were reported more frequently than with placebo.[24]

• Suicidality: Of greatest concern are rare but serious instances of suicidal ideation and behavior, including completed suicides, which have been observed in both the clinical trial program and post-marketing surveillance.[25] This risk appears to be present regardless of a prior history of depression.
• Risk Management: Due to this risk, Roflumilast is not recommended for patients with a history of depression associated with suicidal ideation or behavior. For any patient with a psychiatric history, the prescriber must carefully weigh the potential benefits against the risks. Crucially, patients, their families, and caregivers must be thoroughly counseled to be vigilant for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or any other unusual changes in mood or behavior. Any such changes must be reported to the healthcare provider immediately for re-evaluation of the treatment plan.[25]

5.3 Contraindications and Precautions

The primary contraindication for Roflumilast is moderate to severe liver impairment (Child-Pugh Class B or C).[8] This is due to the drug's extensive hepatic metabolism; impaired liver function can lead to significantly increased drug exposure and a higher risk of adverse events. Caution is also advised when using the drug in patients with mild hepatic impairment (Child-Pugh Class A).[69]

5.4 Significant Drug-Drug Interactions

Roflumilast's reliance on the CYP3A4 and CYP1A2 enzyme systems for its metabolism makes it highly susceptible to clinically significant drug-drug interactions.[2]

• Strong CYP Inducers: Co-administration with strong inducers of CYP enzymes (e.g., rifampicin, carbamazepine, phenobarbital, phenytoin) is not recommended. These agents can dramatically increase the metabolism of Roflumilast and its active N-oxide metabolite, leading to a significant reduction in systemic exposure and a potential loss of therapeutic effectiveness.[25] For instance, co-administration with rifampicin reduced the AUC of the active N-oxide metabolite by 56%.[25]
• Strong CYP Inhibitors and Dual Inhibitors: Conversely, co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole) or dual inhibitors of both CYP3A4 and CYP1A2 (e.g., fluvoxamine, cimetidine, erythromycin) will increase systemic exposure to Roflumilast, potentially increasing the incidence and severity of adverse reactions. The clinical decision to use these drugs concurrently must involve a careful weighing of risks versus benefits.[25] For example, the dual inhibitor fluvoxamine was shown to increase the AUC of the parent Roflumilast by 156%.[25]
• Oral Contraceptives: Certain oral contraceptives containing gestodene and ethinyl estradiol have also been shown to increase Roflumilast exposure and may increase the risk of side effects.[25]

Interacting Drug/Class	Mechanism	Effect on Roflumilast (AUC Change)	Effect on Roflumilast N-oxide (AUC Change)	Clinical Recommendation
Rifampicin	Strong CYP3A4 Inducer	↓ 79%	↓ 56%	Not Recommended
Fluvoxamine	Dual CYP3A4/1A2 Inhibitor	↑ 156%	↑ 52%	Weigh Risk vs. Benefit
Ketoconazole	Strong CYP3A4 Inhibitor	↑ 99%	↑ 3%	Weigh Risk vs. Benefit
Cimetidine	Dual CYP3A4/1A2 Inhibitor	↑ 85%	↑ 27%	Weigh Risk vs. Benefit
Erythromycin	CYP3A4 Inhibitor	↑ 70%	↑ 4%	Weigh Risk vs. Benefit

Section 6: Regulatory and Commercial Landscape

The regulatory and commercial history of Roflumilast is notable, reflecting a bifurcated journey that saw it first established as a niche oral therapy for a specific respiratory disease, followed more than a decade later by a rapid expansion into the broad field of topical dermatology. This trajectory highlights an evolving understanding of the drug's therapeutic potential and risk-management strategies.

6.1 Regulatory Approval History

Roflumilast has received marketing authorization from major regulatory bodies worldwide, with distinct timelines for its oral and topical formulations.

European Medicines Agency (EMA):

• Roflumilast was first approved in the European Union under the brand name Daxas in June/July 2010. The indication was for the maintenance treatment of severe COPD associated with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator therapy.[1] The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that, for this specific high-risk population, the modest benefits of the drug in reducing exacerbations outweighed its known risks.[77]
• A duplicate marketing authorization for the brand name Daliresp was granted in February 2011. However, this was later withdrawn by the marketing authorization holder in January 2018 for commercial reasons, leaving Daxas as the primary brand in the EU.[79]

U.S. Food and Drug Administration (FDA):

• Oral Formulation (Daliresp): The FDA approved Daliresp in February/March 2011 to reduce the risk of COPD exacerbations.[2] The approval process in the U.S. was more challenging than in Europe. The FDA had initially issued a Complete Response Letter in May 2010, and its Pulmonary-Allergy Drugs Advisory Committee had voted against recommending approval, citing concerns over the drug's safety profile, particularly the psychiatric and gastrointestinal side effects.[78] The eventual approval for a narrow indication reflected a careful balancing of benefit and risk.
• Topical Formulations (Zoryve): A new chapter for Roflumilast began in July 2022 with the first approval of a topical formulation. This was followed by a series of rapid approvals for different strengths and indications:
• July 2022: 0.3% Cream for plaque psoriasis in patients aged 12 and older.[49]
• October 2023: Approval expanded for the 0.3% cream to children aged 6 to 11.[49]
• December 2023: 0.3% Foam for seborrheic dermatitis in individuals aged 9 and older.[1]
• July 2024: 0.15% Cream for mild to moderate atopic dermatitis in adults and children down to 6 years of age.[49]
• May 2025 (Projected): 0.3% Foam for plaque psoriasis of the scalp and body in adults and adolescents.[49]

Health Canada:

• Oral Roflumilast was approved for COPD in 2017.[2] The topical cream formulation received approval for plaque psoriasis in April 2023.[1]

This dual regulatory history is significant. The initial, cautious approval of the oral formulation for a very specific, high-need COPD population contrasts sharply with the rapid, successive approvals of the topical formulations for common dermatological conditions over a decade later. This reflects the successful application of formulation science and pharmacokinetic principles to fundamentally alter a drug's benefit-risk profile. By engineering a topical product with high local efficacy and minimal systemic absorption, the developers effectively mitigated the systemic safety concerns that had limited the oral formulation, thereby unlocking the potent anti-inflammatory mechanism of Roflumilast for a new set of diseases.

6.2 Commercial Information

• Brand Names: The drug is marketed under several brand names globally. The most prominent are Daliresp in the United States, Daxas in the European Union for the oral formulation, and Zoryve for the topical formulations worldwide.[2]
• Manufacturers and Marketers: The development and marketing of Roflumilast have involved several pharmaceutical companies, including the original developer Nycomed, followed by Forest Laboratories, Allergan, and AstraZeneca for the respiratory indications. Arcutis Biotherapeutics is responsible for the development and commercialization of the topical Zoryve formulations.[1]
• Legal Status: In all major markets, including the US, EU, UK, Canada, and Australia, Roflumilast is a prescription-only medicine (POM, ℞-only).[2] Generic versions of the oral formulation are now available, which may increase accessibility.[2]

Section 7: Critical Appraisal and Future Perspectives

While Roflumilast has established a clear therapeutic niche, a critical appraisal of the existing evidence reveals limitations and highlights unmet needs in the management of severe COPD. Concurrently, the success of Roflumilast as a first-in-class PDE4 inhibitor has catalyzed research into next-generation molecules, pointing toward a dynamic future for this class of anti-inflammatory agents.

7.1 Limitations of Current Evidence and Unmet Needs in COPD

Despite its proven efficacy in a select patient population, several gaps remain in the evidence base for Roflumilast.

• Lack of Head-to-Head Comparative Trials: A significant limitation is the absence of large, direct, head-to-head randomized controlled trials comparing Roflumilast as an add-on therapy against other guideline-recommended strategies for frequent exacerbators. For instance, there are no direct trials comparing Roflumilast to chronic azithromycin, another therapy used to reduce exacerbations in a similar patient population.[42] This lack of comparative effectiveness data makes it challenging for clinicians to definitively position Roflumilast versus other options in the treatment algorithm based on superiority, forcing decisions to be based on patient phenotype, safety profiles, and tolerability.
• Discrepancies in Real-World Evidence: The translation of efficacy from highly controlled RCTs to real-world effectiveness has yielded mixed results. While some real-world studies support the findings of RCTs, showing a reduction in exacerbations and hospitalizations after initiating Roflumilast [88], others have produced conflicting data. Notably, a large Danish observational cohort study associated Roflumilast use with an increased risk of hospitalization for both exacerbations and pneumonia.[90] This counterintuitive finding is likely attributable to significant confounding by indication, where the drug is prescribed to the most severely ill patients who are already at the highest baseline risk for these events. These discrepancies underscore the need for more robust, well-designed pragmatic trials and real-world effectiveness studies to clarify its true impact in routine clinical practice.
• Uncertainty Regarding Disease Modification: A major unmet need in COPD is the development of therapies that can alter the natural history of the disease by slowing the progressive decline in lung function or reducing mortality. While Roflumilast reduces the frequency of exacerbations—events known to accelerate lung function decline—there is limited long-term data from pivotal trials or their extensions to conclusively demonstrate that it slows the rate of FEV1​ decline over several years.[35] Similarly, evidence on mortality is inconclusive. A large, multinational observational safety study found no increased mortality risk in Norway and Sweden, but a small increase in Germany and the US, again likely due to confounding by indication.[93]

7.2 The Next Generation of PDE4 Inhibition

The therapeutic success of Roflumilast has validated PDE4 as a target, while its limitations, primarily the gastrointestinal and psychiatric side effects, have provided a clear roadmap for improvement. The development of next-generation PDE4 inhibitors is focused on enhancing the benefit-risk ratio through several innovative strategies.[97]

1. Inhaled Formulations: To maximize drug delivery to the lungs while minimizing systemic exposure, several inhaled PDE4 inhibitors are in development (e.g., Tanimilast/CHF6001). This approach directly addresses the root cause of Roflumilast's systemic side effects and holds the potential for a much-improved tolerability profile.[97]
2. Isoform-Selective Inhibitors: Research suggests that the anti-inflammatory effects of PDE4 inhibition are primarily mediated by the PDE4B subtype, whereas the emetic side effects are linked to PDE4D inhibition. This has spurred the development of next-generation inhibitors designed to selectively target PDE4B, with the goal of retaining efficacy while reducing nausea and vomiting.[98]
3. Dual-Mechanism Inhibitors: A particularly promising strategy is the creation of molecules that inhibit both PDE4 and PDE3. These dual PDE3/4 inhibitors (e.g., Ensifentrine/RPL554) are designed to provide both anti-inflammatory effects (from PDE4 inhibition) and direct bronchodilation (from PDE3 inhibition) in a single inhaled molecule. This approach could offer a more comprehensive treatment for COPD than either mechanism alone.[97]

The evolution of this drug class demonstrates a classic cycle in pharmaceutical development: a first-in-class drug like Roflumilast serves as a crucial proof-of-concept, validating a therapeutic target but also revealing its limitations. These limitations then become the design criteria for its successors, which aim to refine the mechanism, improve delivery, and ultimately create therapies with a wider therapeutic index applicable to a broader patient population.

7.3 Future Therapeutic Horizons for Roflumilast

The potent, systemic anti-inflammatory effects of oral Roflumilast suggest a therapeutic potential that may extend beyond its currently approved indications. Reflecting the expanding interest in its mechanism, clinical trials have been conducted or are ongoing to investigate its utility in a diverse range of other inflammatory and metabolic conditions, including non-alcoholic steatohepatitis (NASH), ulcerative colitis, and even neurological disorders such as Fragile X Syndrome and depression.[64] The outcomes of these investigations will determine whether the therapeutic scope of Roflumilast can be broadened in the future.

Section 8: Expert Recommendations and Clinical Practice Synopsis

The effective and safe use of Roflumilast in clinical practice requires a nuanced approach that goes beyond simply prescribing the medication. It necessitates a systematic process of careful patient phenotyping, proactive management of predictable adverse effects, and a commitment to shared decision-making. The success of therapy is inextricably linked to the quality of the clinical management surrounding the prescription.

8.1 Patient Selection: Applying the "Treatable Traits" Model

The ideal candidate for oral Roflumilast therapy is not just any patient with COPD, but one who exhibits a specific cluster of "treatable traits" that have been shown to predict a favorable response. Clinicians should use the following criteria to identify suitable candidates:

• Disease Severity and Exacerbation History: The patient must have severe or very severe COPD (GOLD 3 or 4), confirmed by a post-bronchodilator FEV1​ < 50% of the predicted value. Crucially, they must be a frequent exacerbator, defined as having a history of two or more moderate exacerbations or at least one severe exacerbation requiring hospitalization in the previous year, despite being on optimal inhaled maintenance therapy (ideally triple therapy with an ICS/LABA/LAMA).
• Clinical Phenotype: The presence of chronic bronchitis, characterized by a chronic productive cough, is a key phenotypic marker that strongly predicts a positive response and is part of the formal indication.[27]
• Biomarker Profile: While not mandatory for initiation, a blood eosinophil count of ≥150 cells/µL can serve as a valuable predictive biomarker, identifying patients who are more likely to derive a greater benefit, particularly those with a history of hospitalization.[43]
• Exclusion Criteria: A thorough patient history is essential to screen for contraindications and high-risk conditions. This includes excluding patients with moderate-to-severe liver disease (Child-Pugh B or C) and those with a significant personal or family history of depression or suicidal ideation.[24]

8.2 Treatment Initiation and Management of Adverse Effects

Proactive management of the well-known adverse effects of Roflumilast is critical to improving adherence and achieving long-term therapeutic success.

• Dosing Strategy: To enhance initial tolerability, clinicians should consider initiating therapy with a 250 mcg daily dose for the first 4 weeks. Patients must be counseled that this is a starting dose to allow their body to acclimate and is not the effective therapeutic dose. After four weeks, the dose should be escalated to the target maintenance dose of 500 mcg once daily.[8]
• Managing Gastrointestinal Side Effects: Patients should be informed upfront that diarrhea and nausea are common, typically occur early in treatment, and are often transient, resolving with continued use. Taking the medication with food may help alleviate these symptoms in some individuals. If GI symptoms are severe or persist beyond the initial few weeks, the therapy should be re-evaluated.
• Managing Weight Loss: Patients should be counseled about the potential for weight loss. Regular weight monitoring at each clinic visit is a mandatory part of management. For patients who are already underweight or exhibit signs of frailty, the risk of further weight loss may outweigh the potential benefits of therapy. In contrast, for overweight or obese patients, this effect may be neutral or even beneficial, but it still requires diligent monitoring to ensure it does not become excessive or clinically significant.[66]
• Managing Psychiatric Symptoms: A proactive and transparent discussion about the risk of mood changes, insomnia, anxiety, and depression is essential before starting treatment. This conversation should include the patient's family or caregivers. All parties should be provided with clear instructions to report any such changes immediately. Clinicians should maintain a low threshold for discontinuing therapy if significant psychiatric symptoms emerge.[25]

8.3 Monitoring and Follow-Up

Ongoing monitoring is essential to assess both the efficacy and safety of Roflumilast therapy.

• Efficacy: The primary measure of efficacy is a reduction in the frequency and severity of exacerbations compared to the patient's history.
• Safety: Follow-up visits should include a systematic review for adverse effects, with specific queries about GI symptoms, mood changes, and sleep patterns. Patient weight should be measured and documented at each visit.
• Patient-Reported Outcomes: Tools such as the COPD Assessment Test (CAT) or the St. George's Respiratory Questionnaire (SGRQ) can be used to track changes in health status and quality of life. Evidence from the OPUS trial showed a statistically significant improvement in SGRQ scores in the frequent exacerbator subgroup treated with Roflumilast.[105]

8.4 Shared Decision-Making

The decision to initiate Roflumilast is an ideal scenario for shared decision-making. Given that the benefits are concentrated in a specific patient subgroup and are balanced against a notable side effect profile, a collaborative discussion is paramount. The clinician should transparently present the potential benefits (a probabilistic reduction in future exacerbations and hospitalizations) versus the known risks (GI side effects, weight loss, psychiatric events), as well as the financial cost of the therapy. This allows the patient to weigh the evidence in the context of their personal values, risk tolerance, and treatment goals, leading to a more informed and personalized therapeutic choice.[107]

Works cited

1. Roflumilast | C17H14Cl2F2N2O3 | CID 449193 - PubChem, accessed July 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/449193
2. Roflumilast - Wikipedia, accessed July 31, 2025, https://en.wikipedia.org/wiki/Roflumilast
3. Roflumilast | CAS 162401-32-3 | SCBT - Santa Cruz Biotechnology, accessed July 31, 2025, https://www.scbt.com/p/roflumilast-162401-32-3
4. Roflumilast: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 31, 2025, https://go.drugbank.com/drugs/DB01656
5. Molecular Properties of Phosphodiesterase 4 and Its Inhibition by ..., accessed July 31, 2025, https://www.mdpi.com/1420-3049/30/3/692
6. Pharmacokinetic evaluation of roflumilast, accessed July 31, 2025, https://www.tandfonline.com/doi/pdf/10.1517/17425255.2011.632409
7. Roflumilast (APTA-2217) | PDE4 Inhibitor | MedChemExpress, accessed July 31, 2025, https://www.medchemexpress.com/Roflumilast.html
8. DALIRESP® (roflumilast) – For Adults with Severe COPD, accessed July 31, 2025, https://www.daliresp.com/
9. Contact US | DALIRESP®(roflumilast) | For HCPs, accessed July 31, 2025, https://www.daliresphcp.com/contact-us.html/
10. Important Safety Information | DALIRESP® (roflumilast) | For HCPs, accessed July 31, 2025, https://www.daliresphcp.com/important-safety-information.html
11. Roflumilast - Bio-X ™ | 162401-32-3 | BR164364 - Biosynth, accessed July 31, 2025, https://www.biosynth.com/p/BR164364/162401-32-3-roflumilast-bio-x
12. Roflumilast: a review of its use in the treatment of COPD - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4708192/
13. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease | American Journal of Respiratory and Critical Care Medicine, accessed July 31, 2025, https://www.atsjournals.org/doi/full/10.1164/rccm.201503-0543OC
14. Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist - Frontiers, accessed July 31, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.598702/full
15. DALIRESP® (roflumilast) Mechanism of Action | For HCPs, accessed July 31, 2025, https://www.daliresphcp.com/roflumilast-mechanism-of-action.html
16. Roflumilast significantly decreased inflammatory biomarkers in induced sputum in current smokers patients with severe chronic obstructive pulmonary disease - ERS Publications, accessed July 31, 2025, https://publications.ersnet.org/content/erj/40/suppl56/p3460
17. PDE4 Inhibitor Overview - Medical Affairs - Arcutis Biotherapeutics, accessed July 31, 2025, https://medicalaffairs.arcutis.com/investigational-therapies/pde4-inhibitor/
18. Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11784981/
19. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4642210/
20. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/26151090/
21. Update in Chronic Obstructive Pulmonary Disease 2015 | American Journal of Respiratory and Critical Care Medicine, accessed July 31, 2025, https://www.atsjournals.org/doi/10.1164/rccm.201602-0213UP
22. Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease - The Korean Journal of Internal Medicine, accessed July 31, 2025, https://www.kjim.org/upload/kjim-2020-035.pdf
23. Long-term studies involving roflumilast | Download Table - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/figure/Long-term-studies-involving-roflumilast_tbl2_49618554
24. Roflumilast Disease Interactions - Drugs.com, accessed July 31, 2025, https://www.drugs.com/disease-interactions/roflumilast.html?professional=1
25. ROFLUMILAST tablet - DailyMed, accessed July 31, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84145572-f320-4c3f-ab29-bd9f6c18746c
26. Topical Roflumilast Cream Results in Higher Skin Concentrations - HCPLive, accessed July 31, 2025, https://www.hcplive.com/view/topical-roflumilast-cream-higher-skin-concentrations
27. What is the role of roflumilast in chronic obstructive pulmonary disease?, accessed July 31, 2025, https://www.ccjm.org/content/84/1/13
28. Exacerbation Treatment for Severe COPD |DALIRESP® (roflumilast) | For HCPs, accessed July 31, 2025, https://www.daliresphcp.com/
29. Q:What is the role of roflumilast in chronic obstructive pulmonary disease? - Cleveland Clinic Journal of Medicine, accessed July 31, 2025, https://www.ccjm.org/content/ccjom/84/1/13.full.pdf
30. 1-Minute Consult: What Is the Role of Roflumilast in COPD?, accessed July 31, 2025, https://consultqd.clevelandclinic.org/1-minute-consult-what-is-the-role-of-roflumilast-in-copd
31. Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT00313209
32. Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) | ClinicalTrials.gov, accessed July 31, 2025, https://www.clinicaltrials.gov/study/NCT00424268
33. Effect of roflumilast in chronic obstructive pulmonary disease (COPD ..., accessed July 31, 2025, https://www.astrazenecaclinicaltrials.com/study/BY217%2FM2-128/
34. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD - Dove Medical Press, accessed July 31, 2025, https://www.dovepress.com/article/download/4834
35. Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD, accessed July 31, 2025, https://smw.ch/index.php/smw/article/download/1535/1955?inline=1
36. Roflumilast for the treatment of respiratory disease: review of the Phase II and III trials - Open Access Journals, accessed July 31, 2025, https://www.openaccessjournals.com/articles/roflumilast-for-the-treatment-of-respiratory-disease-review-of-the-phase-ii-and-iii-trials.pdf
37. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination - myCME, accessed July 31, 2025, https://media.mycme.com/documents/133/martinez_2015_33026.pdf
38. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/25684586/
39. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β 2 -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE 2 SPOND). A Randomized Clinical Trial - ATS Journals, accessed July 31, 2025, https://www.atsjournals.org/doi/full/10.1164/rccm.201607-1349OC
40. Effect of roflumilast in patients with severe COPD and a history of hospitalisation, accessed July 31, 2025, https://publications.ersnet.org/content/erj/50/1/1700158
41. Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease | American Journal of Respiratory and Critical Care Medicine, accessed July 31, 2025, https://www.atsjournals.org/doi/10.1164/rccm.200610-1563OC
42. Comparative Effectiveness of Roflumilast and Azithromycin for the Treatment of Chronic Obstructive Pulmonary Disease, accessed July 31, 2025, https://journal.copdfoundation.org/jcopdf/id/1356/Comparative-Effectiveness-of-Roflumilast-and-Azithromycin-for-the-Treatment-of-Chronic-Obstructive-Pulmonary-Disease
43. Determinants of Response to Roflumilast in Severe Chronic ..., accessed July 31, 2025, https://www.atsjournals.org/doi/full/10.1164/rccm.201712-2493OC
44. Treatable Traits in COPD – A Proposed Approach - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8609199/
45. Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD | European Respiratory Society, accessed July 31, 2025, https://publications.ersnet.org/content/erjor/7/2/00934-2020
46. Determinants of Response to Roflumilast in Severe ... - ATS Journals, accessed July 31, 2025, https://www.atsjournals.org/doi/pdf/10.1164/rccm.201712-2493OC
47. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/29763572/
48. Roflumilast (topical application route) - Side effects & dosage - Mayo Clinic, accessed July 31, 2025, https://www.mayoclinic.org/drugs-supplements/roflumilast-topical-application-route/description/drg-20537759
49. Zoryve (roflumilast) FDA Approval History - Drugs.com, accessed July 31, 2025, https://www.drugs.com/history/zoryve.html
50. Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-1) - ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT04211363
51. Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-OLE) - ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT04286607
52. Oral roflumilast for plaque psoriasis: Results from a 24-week real-world study - PsOPsA Hub, accessed July 31, 2025, https://psoriasis-hub.com/medical-information/oral-roflumilast-for-plaque-psoriasis-results-from-a-24-week-real-world-study
53. Off-Label Topical and Oral Roflumilast Treatment in Dermatology: A Systematic Review | Request PDF - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/384605181_Off-Label_Topical_and_Oral_Roflumilast_Treatment_in_Dermatology_A_Systematic_Review
54. Roflumilast: Uses, Application, and Side-effects - DermNet, accessed July 31, 2025, https://dermnetnz.org/topics/roflumilast
55. Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD), accessed July 31, 2025, https://www.arcutis.com/arcutis-announces-positive-long-term-results-of-roflumilast-cream-0-15-showing-durable-and-improved-efficacy-over-time-and-favorable-safety-profile-in-treatment-of-mild-to-moderate-atopic-dermatitis/
56. Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients with Chronic Plaque Psoriasis, accessed July 31, 2025, https://scholarlycommons.henryford.com/dermatology_mtgabstracts/249/
57. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/37709133/
58. Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study - Taylor & Francis Online, accessed July 31, 2025, https://www.tandfonline.com/doi/pdf/10.1080/09546634.2025.2464107
59. (PDF) Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study, accessed July 31, 2025, https://www.researchgate.net/publication/388898632_Oral_roflumilast_for_psoriasis_a_real-world_24-week_prospective_cohort_study
60. Full article: Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study, accessed July 31, 2025, https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2464107
61. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/38224734/
62. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review-Bohrium, accessed July 31, 2025, https://www.bohrium.com/paper-details/translated-aticle-topical-and-oral-roflumilast-in-dermatology-a-narrative-review/977538696091795507-20873
63. Rosacea Recruiting Phase 2 Trials for Roflumilast (DB01656) | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/indications/DBCOND0019774/clinical_trials/DB01656?phase=2&status=recruiting
64. What clinical trials have been conducted for Roflumilast?, accessed July 31, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-roflumilast
65. www.daliresphcp.com, accessed July 31, 2025, https://www.daliresphcp.com/important-safety-information.html#:~:text=In%208%20controlled%20clinical%20trials,vs%201.1%25)%2C%20and%20decreased%252C%2520and%2520decreased&sa=D&source=editors&ust=1753956327262570&usg=AOvVaw0i7Li01TklkZtd2uLrZfRg)
66. DALIRESP (roflumilast) tablets - accessdata.fda.gov, accessed July 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022522s008lbl.pdf
67. DALIRESP® (roflumilast) Side Effects and Dosage, accessed July 31, 2025, https://www.daliresp.com/daliresp-side-effects.html
68. Daxas, INN-roflumilast - European Medicines Agency, accessed July 31, 2025, https://www.ema.europa.eu/en/documents/product-information/daxas-epar-product-information_en.pdf
69. Daliresp (roflumilast) dosing, indications, interactions, adverse effects, and more, accessed July 31, 2025, https://reference.medscape.com/drug/daliresp-roflumilast-999626
70. FULL PRESCRIBING INFORMATION ... - accessdata.fda.gov, accessed July 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022522s009lbl.pdf
71. Study Details | Strategy to Improve Adherence of Roflumilast | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT02018432
72. Roflumilast Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 31, 2025, https://www.drugs.com/sfx/roflumilast-side-effects.html
73. Safety and Adverse Reactions | DALIRESP®(roflumilast) | For HCPs, accessed July 31, 2025, https://www.daliresphcp.com/roflumilast-safety-and-adverse-reactions.html
74. Daliresp (roflumilast): Uses, Side Effects, Dosage & More - GoodRx, accessed July 31, 2025, https://www.goodrx.com/daliresp/what-is
75. Roflumilast (oral route) - Side effects & dosage - Mayo Clinic, accessed July 31, 2025, https://www.mayoclinic.org/drugs-supplements/roflumilast-oral-route/description/drg-20074855
76. Daxas - Medicinal Products Database - HALMED, accessed July 31, 2025, https://www.halmed.hr/en/Lijekovi/Baza-lijekova/Daxas/9547/
77. Daxas | European Medicines Agency (EMA), accessed July 31, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/daxas
78. Roflumilast Approved in Europe for Chronic Obstructive Pulmonary Disease - Medscape, accessed July 31, 2025, https://www.medscape.com/viewarticle/724903
79. Daliresp | European Medicines Agency (EMA), accessed July 31, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/daliresp
80. Daliresp (roflumilast) FDA Approval History - Drugs.com, accessed July 31, 2025, https://www.drugs.com/history/daliresp.html
81. Buy Daxas (roflumilast) (roflumilast) Online • Price & Costs | Everyone.org, accessed July 31, 2025, https://everyone.org/daxas-roflumilast
82. DAXAS® | AstraZeneca Canada, accessed July 31, 2025, https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/daxas-consumer-information-leaflet-en.pdf
83. Study Details | Post Marketing Surveillance of Roflumilast in Korea | ClinicalTrials.gov, accessed July 31, 2025, https://www.clinicaltrials.gov/study/NCT02068456?term=ROFLUMILAST&rank=9
84. Long-term observational study of the safety of Roflumilast, accessed July 31, 2025, https://www.astrazenecaclinicaltrials.com/study/D7120R00003/
85. (PDF) Cost-effectiveness of roflumilast as an add-on to triple inhaled ..., accessed July 31, 2025, https://www.researchgate.net/publication/327398570_Cost-effectiveness_of_roflumilast_as_an_add-on_to_triple_inhaled_therapy_vs_triple_inhaled_therapy_in_patients_with_severe_and_very_severe_COPD_associated_with_chronic_bronchitis_in_the_UK
86. Roflumilast added to triple therapy in patients with severe COPD: a real life study - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/25445930/
87. Efficiency and safety of roflumilast combined with long-acting ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5059333/
88. Differential response to roflumilast in patients with chronic ... - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/38505074/
89. Efficacy and safety profile of roflumilast in a real-world experience - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6531746/
90. Roflumilast in severely ill patients with chronic obstructive pulmonary disease with frequent exacerbations: real-life outcomes | European Respiratory Society, accessed July 31, 2025, https://publications.ersnet.org/content/erj/56/suppl64/178
91. Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations - MDPI, accessed July 31, 2025, https://www.mdpi.com/2077-0383/9/5/1442
92. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history, accessed July 31, 2025, https://publications.ersnet.org/content/erj/38/3/553
93. (PDF) Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/383292063_Long-Term_Safety_of_Roflumilast_in_Patients_with_Chronic_Obstructive_Pulmonary_Disease_a_Multinational_Observational_Database_Cohort_Study
94. Full article: Long-Term Safety of Roflumilast in Patients with Chronic ..., accessed July 31, 2025, https://www.tandfonline.com/doi/full/10.2147/COPD.S465517
95. Roflumilast Linked to Higher 5-Year Mortality in Patients With COPD in US, Germany, accessed July 31, 2025, https://www.ajmc.com/view/roflumilast-linked-to-higher-5-year-mortality-in-patients-with-copd-in-us-germany
96. Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11345007/
97. PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11748061/
98. PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review - The Open Respiratory Medicine Journal, accessed July 31, 2025, https://openrespiratorymedicinejournal.com/VOLUME/18/ELOCATOR/e18743064340418/FULLTEXT/
99. Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10689637/
100. Phosphodiesterase-4 Inhibitors for the Treatment of ... - Frontiers, accessed July 31, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01048/full
101. PDE4 Inhibitors and their Potential Combinations for the Treatment ..., accessed July 31, 2025, https://openrespiratorymedicinejournal.com/VOLUME/18/ELOCATOR/e18743064340418/
102. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases - Frontiers, accessed July 31, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1407871/full
103. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review, accessed July 31, 2025, https://www.actasdermo.org/en-translated-aticle-topical-oral-roflumilast-articulo-S0001731024000243
104. Study Details | Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD) | ClinicalTrials.gov, accessed July 31, 2025, https://www.clinicaltrials.gov/study/NCT01630200
105. Effect of Roflumilast Treatment on Healthrelated Quality of Life in ..., accessed July 31, 2025, https://shmabstracts.org/abstract/effect-of-roflumilast-treatment-on-healthrelated-quality-of-life-in-patients-with-chronic-obstructive-pulmonary-disease/
106. St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database, accessed July 31, 2025, https://journal.copdfoundation.org/jcopdf/id/1148/St-Georges-Respiratory-Questionnaire-Score-Predicts-Outcomes-in-Patients-with-COPD-Analysis-of-Individual-Patient-Data-in-the-COPD-Biomarkers-Qualification-Consortium-Database
107. "Roflumilast does not decrease COPD exacerbations in adequately ..., accessed July 31, 2025, https://digitalcommons.wayne.edu/crp/vol5/iss1/2/